Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
Patients aged 18 and older with moderate to severe orbitopathy;
Patients followed in endocrinology with the goal of achieving euthyroidism;
Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);
Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;
Patients who have undergone bone or fat decompression surgery;
Patients with severe corneal involvement (Grade B or C; NO SPECS classification);
Patients with optic neuropathy (Grade B and C; NO SPECS classification);
Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;
The data collection concerns patients with Graves' orbitopathy who have received corticosteroid treatment and second-line treatment (immunosuppressants, biotherapy) since 2015, 2021, or 2022. A decision was made to limit the inclusion to patients who started second-line treatment between January 2022 and December 2023, with clinical follow-up until the end of 2024, in order to limit selection bias and ensure an adequate follow-up period. The inclusion period extends until June 2025.
Other
Retrospective
Not listed
Response to second-line basedow treatment
Practices in France regarding the use of these second-line treatments appear to be heterogeneous, and their effectiveness has never been compared through randomized studies. investigators propose to collect and analyze the therapeutic outcomes of second-line treatment in patients with Graves' orbitopathy. The data collection concerns patients with Graves' orbitopathy who have received corticosteroid therapy and a second-line treatment (immunosuppressant, biotherapy) since 2022. Data from the medical records of patients included.
Click on the lead sponsor to view all of their trials.
